HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INGN
Inogen, Inc.
INGN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INGN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
INGN's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INGN PE Valuation
INGN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect INGN's losses to shrink, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
INGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.31 | -$0.30 |
| Q2 2026 | -$0.90 | +$0.16 |
| Q1 2026 | -$0.91 | +$0.24 |
| Q4 2025 | -$0.86 | +$0.66 |
| Q3 2025 | -$1.01 | +$1.25 |
| Q2 2025 | -$1.06 | +$2.92 |
| Q1 2025 | -$1.15 | +$3.01 |
| Q4 2024 | -$1.52 | +$2.90 |
INGN has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over INGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over INGN on profitability, with a higher operating margin.
INGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $77.2M | -16% |
| Q2 2026 | $95.1M | +3% |
| Q1 2026 | $85.1M | +3.4% |
| Q4 2025 | $81.7M | +2% |
| Q3 2025 | $92.4M | +4% |
| Q2 2025 | $92.3M | +4% |
| Q1 2025 | $82.3M | +5.5% |
| Q4 2024 | $80.1M | +5.5% |
INGN's revenue fell from its 2022 peak and has held roughly level since: $77M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | -13 points |
| Q2 2026 | -5.4% | +1.3 points |
| Q1 2026 | -11% | -1.7 points |
| Q4 2025 | -11% | +2.8 points |
| Q3 2025 | -7.7% | +1.1 points |
| Q2 2025 | -6.6% | +1.3 points |
| Q1 2025 | -9.3% | +12 points |
| Q4 2024 | -14% | +24 points |
INGN's operating margin was −20% last quarter, down 12 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over INGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
INGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.8M | -397% |
| Q2 2026 | $2.2M | -39% |
| Q1 2026 | -$6.9M | +$10.2M |
| Q4 2025 | -$1.9M | +$1.4M |
| Q3 2025 | $1.6M | -70% |
| Q2 2025 | $3.7M | -45% |
| Q1 2025 | -$17.1M | -$11M |
| Q4 2024 | -$3.3M | +$1.2M |
INGN's free cash flow was −$11M over the past year, against −$15M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over INGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.2% | -584K shares |
| 1 year | -2.3% | -614K shares |
| 3 years | +14% | +3.2M shares |
| 5 years | +16% | +3.6M shares |
| Available history | +21% | +4.6M shares |
INGN has 26M diluted shares, down 2.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.7M |
| Q2 2026 | $5.6M |
| Q1 2026 | $1.9M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
INGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -122.1x | Net Cash |
| Q1 2022 | -13.6x | Net Cash |
| Q4 2021 | -8.9x | Net Cash |
| Q3 2021 | -9.0x | Net Cash |
| Q2 2021 | -13.6x | Net Cash |
| Q1 2021 | -80.5x | Net Cash |
| Q4 2020 | -103.4x | Net Cash |
| Q3 2020 | -110.1x | Net Cash |
INGN has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.4 | Neutral |
| Stochastic | 47.7 | Neutral |
INGN's weekly RSI is 43 (neutral) and its Stochastic is 48 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INGN PE vs Healthcare Sector
| Metric | INGN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INGN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
INGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.17 | 8.9% below |
| 20 week MA | $6.02 | 6.6% below |
| 50 week MA | $6.28 | 11% below |
| 100 week MA | $7.07 | 21% below |
| 200 week MA | $8.28 | 32% below |
INGN is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
INGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.5 | $43.3 | -37% |
| 2021 | $43.3 | $32.7 | -25% |
| 2022 | $32.7 | $19.9 | -39% |
| 2023 | $19.9 | $5.49 | -72% |
| 2024 | $5.49 | $8.58 | +56% |
| 2025 | $8.58 | $6.80 | -21% |
| 2026 YTD | $6.80 | $5.62 | -17% |
INGN has the edge over HIMS on returns for 2026, with the stronger performance.